NeoCore Technology Co (4131) Fair Value & Analysis
Healthcare · TW · Market cap 1.5B TWD
Fair value as of: Jun 24, 2026
Analysis
NeoCore Technology Co (4131) currently trades at 36.80 TWD, while our model-based Fair Value estimate is 23.04 TWD — implying the stock looks roughly 37.4% overvalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
NeoCore Technology Co., Ltd. designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices. The company's products include food safety examination systems, human diagnosis arrays systems, agriculture examination systems, food examination arrays systems, and laboratory instruments, as well as DNA kits. It also offers laboratory planning, design, and other services. In addition, the company engages in the wholesale and retail of contact lenses. The company was formerly known as DR. Chip Biotechnology Incorporation and changed its name to NeoCore Technology Co., Ltd. in July 2023. NeoCore Technology Co., Ltd. was founded in 1987 and is headquartered in Tainan City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is NeoCore Technology Co (4131) undervalued?
What is the fair value of 4131?
What is the quality score of 4131?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.